首页> 美国卫生研究院文献>Gastrointestinal Cancer Research : GCR >ABSTR 0912 – Proffered Oral Presentation: Systemic Delivery of Liposome-Incorporated Adrenomedullin Receptor (ADMR) Small Interfering RNA Against Tumor and Its Microenvironment Reduced Pancreatic Tumor Growth
【2h】

ABSTR 0912 – Proffered Oral Presentation: Systemic Delivery of Liposome-Incorporated Adrenomedullin Receptor (ADMR) Small Interfering RNA Against Tumor and Its Microenvironment Reduced Pancreatic Tumor Growth

机译:ABSTR 0912 –提供口服介绍:脂质体掺入的肾上腺髓质素受体(ADMR)小分子干扰RNA对抗肿瘤及其微环境的作用降低了胰腺肿瘤的生长

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background:Pancreatic cancer is a major oncologic challenge due to its aggressive growth and metastasis. Our previous study showed that adrenomedullin (AM) is highly expressed in pancreatic cancer and stimulates pancreatic cancer cells leading to increased tumor growth and metastasis. The current study examines the role of specific AM receptors on tumor and cells resembling the tumor microenvironment (human pancreatic stellate - HPSC, human umbilical vein – HUVEC, and mouse lung endothelial cells - MLEC) and investigates the receptor involved in the autocrine role of AM.
机译:背景:胰腺癌由于其侵袭性生长和转移而成为主要的肿瘤学挑战。我们以前的研究表明肾上腺髓质素(AM)在胰腺癌中高表达并刺激胰腺癌细胞,导致肿瘤生长和转移增加。 肿瘤和类似于肿瘤微环境的细胞(人胰星状-HPSC,人脐静脉-HUVEC和小鼠肺内皮细胞-MLEC)上的AM受体,并研究了参与AM的自分泌作用的受体。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号